Investors in Regeneron reminded of upcoming class action lawsuit by Levi & Korsinsky

Levi & Korsinsky is alerting investors of Regeneron Pharmaceuticals about an ongoing class-action lawsuit with a lead plaintiff deadline of March 10, 2025. The lawsuit accuses Regeneron of making false and misleading statements regarding its business practices, financial performance, and prospects. Investors who purchased Regeneron securities between June 18, 2020, and November 9, 2024, are eligible to participate in the lawsuit and seek compensation for any losses incurred.

The complaint against Regeneron alleges that the company misrepresented the results of its Phase 3 trials for a drug used to treat Diabetic Macular Edema (DME). The lawsuit claims that Regeneron overstated the drug’s efficacy and safety, misleading investors and causing them to suffer financial losses. Additionally, it is alleged that Regeneron failed to disclose adverse events related to the drug, further deceiving investors about the product’s viability in the market.

Furthermore, the lawsuit accuses Regeneron of making false statements about its financial performance and growth prospects. The company is accused of artificially inflating its stock price by providing misleading information about its revenue projections and business outlook. Investors who relied on these misrepresentations suffered financial harm when the truth about Regeneron’s actual financial health came to light.

Investors who purchased Regeneron securities during the specified timeframe and incurred financial losses as a result of the alleged misconduct are encouraged to join the class-action lawsuit. By participating in the lawsuit, investors have the opportunity to seek compensation for their losses and hold Regeneron accountable for its misleading statements and improper business practices.

The lead plaintiff deadline for the class-action lawsuit against Regeneron is March 10, 2025. Investors who wish to participate in the lawsuit must file a motion to serve as lead plaintiff by this date. By serving as lead plaintiff, investors can actively participate in the litigation and represent the interests of all class members who suffered losses as a result of Regeneron’s alleged misconduct.

Levi & Korsinsky is a nationally recognized law firm specializing in securities litigation and class-action lawsuits. The firm has a proven track record of successfully representing investors in cases involving corporate fraud, securities violations, and misleading business practices. Investors who have suffered financial losses due to Regeneron’s alleged misconduct are encouraged to contact Levi & Korsinsky to learn more about their legal rights and options for seeking compensation.

Overall, investors who purchased Regeneron securities between June 18, 2020, and November 9, 2024, and suffered financial losses as a result of the company’s alleged false and misleading statements have the opportunity to seek justice through the ongoing class-action lawsuit. By participating in the lawsuit, investors can hold Regeneron accountable for its misconduct and potentially recover damages for their losses.